JANX earnings date and last-quarter result: last quarter beat, P/E -8.49. Updated 2026-07-23.
Janux Therapeutics (JANX) Research Hub
Janux Therapeutics (JANX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 16.69 USD (+0.18%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.49, market cap 0.96B. This hub links to the full technical, earnings and options research available for JANX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 16.69 USD (+0.18%) |
| 52-week range | 13.58 USD – 20.31 USD |
| Trend regime | Range |
| 14-day RSI | 49.1 (Neutral) |
| Trailing P/E | -8.49 |
| Market cap | 0.96B |
| Dividend yield | 0.00% |
Available research for JANX
Covered Call on JANX: how it works, illustrative setup around the real 16.69 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on JANX: how it works, illustrative setup around the real 16.69 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on JANX: how it works, illustrative setup around the real 16.69 USD price, max profit/loss, breakeven and when to use it. Educational.
JANX technical analysis: range, last 16.69 USD, RSI 49.1, 52w range 13.58 USD–20.31 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is JANX in?
Janux Therapeutics (JANX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is JANX in an uptrend or downtrend?
As of 2026-10-26, JANX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is JANX's trailing P/E ratio?
JANX's trailing P/E is -8.49, with a market cap of 0.96B. See the earnings research page for full valuation detail.